Introduction
Fas ligand (Fas-L), TNF␣ and TRAIL belong to the large family of TNF-like signal-inducing proteins, and their corresponding receptors belong to the large family of TNF-like signal transduction receptor proteins. The Fas and Fas-L system is one of the most studied signal transduction systems in this family of proteins. [1] [2] [3] [4] Fas-L functions primarily as a death signal and induces programmed cell death following trimerization of Fas, resulting in binding of FADD and recruitment/activation of a downstream initiator caspase, caspase-8, followed by subsequent activation of the executioner caspase, caspase-3. 4, 5 TRAIL, similar to Fas, induces a death signal following binding to the DR-4 or DR-5 TRAIL-receptor. 6, 7 However, the exact identity of TRAIL adapter molecule, and the exact caspase involved were not as yet identified. 4, [8] [9] [10] [11] Bcl-2 is a highly conserved, ubiquitous, membrane protein 12 associated mostly with the outer membranes of mitochondria and nuclei. 13 It is widely accepted that bcl-2 is a survival factor for many cells 14 and the over-expression of bcl-2, observed in many cancer cells results in chemoresistance and in the blocking of apoptosis. 15, 16 Although bcl-2 can rescue cells from apoptosis induced by a wide variety of insults, the role of bcl-2 in protecting against Fas-mediated apoptosis is still controversial. [17] [18] [19] [20] [21] [22] [23] [24] We have recently reported that forced expression of bcl-2 confers resistance against dexamethasone [25] [26] [27] and paclitaxelinduces apoptosis. 28 However, melphalan 29 and gemcitabineinduced apoptosis 28 is not blocked by bcl-2. More recently, we have shown that anti-Fas-induced apoptosis could not be blocked by overexpression of bcl-2 in MM cell lines. 30 In this paper we provide first time evidence that TRAIL is a potent inducer of apoptosis in MM cell lines and in freshly isolated 30 to include TRAIL in the TNF family of apoptotic signals that are not blocked by bcl-2, in MM cells.
Materials and methods

Cell lines
Myeloma cell lines ARH-77 and 8226 were obtained from ATCC (Rockville, MD, USA). The ARP-1 myeloma cell line was generated in University of Arkansas for Medical Sciences. 31 Bcl-2 transfected cell lines (designated ARP/SFFV or 8226/SFFV and vector control cell lines) were generated and maintained with G-418 as described before. 27 
TRAIL
Purified human recombinant leucine-zipper containing TRAIL was a kind gift from Immunex (Seattle, WA, USA).
Cell culture and induction of apoptosis with TRAIL
Cells (5 × 10 5 /ml) were cultured in 1 ml of RPMI 1640 medium supplemented with 15% FCS (GIBCO, Grand Island, NY, USA), in a 24-well plate. TRAIL (0-160 ng/ml) was added and wells were harvested after 24 and 48 h, and were tested for the number of viable cells by the trypan blue dye exclusion and for determination of apoptosis by the Hoechst staining method. Staining with Hoechst 33342 (Sigma, St Louis, MO, USA) was done as described before. 32 Cell (100 000) were stained in culture medium containing 1 g/ml of the dye. Stained cells were viewed under a fluorescence microscope as described previously and at least 500 cells with condensed/fragmented nuclei were scored for determination of apoptosis. 32 Spontaneous apoptosis in the control wells was about 5% for all cell lines tested.
Staining for CD38
bright /CD45 − myeloma cells and flow sorting of myeloma cells Bone marrow and peripheral blood samples were obtained from consenting patients. The mononuclear cell fraction was obtained following Ficoll-Hypaque separation. Staining for myeloma cells and flow sorting of myeloma cells was performed as described before. 33 Briefly, for analysis of percent myeloma cells, tubes containing 1 × 10 6 bone marrow mononuclear cells were placed in 100 l of PBS plus 1% BSA and isotypic control immunoglobulin, or CD38-PE and CD45-FITC antibodies (all from BDIS, Mountain View, CA, USA) were added and tubes incubated for 30 min at 4°C. Stained cells were analyzed by flow cytometry (FACSstar Plus; BDIS, San Jose, CA, USA) and results quantitated by the CellQuest program. Ten thousand cells were analyzed. For cell sorting 1 × 10 7 bone marrow mononuclear cells were used. Flow sorting of myeloma cells was performed using the FACSstar Plus flow sorter (Turbo-Fast Sorter, BDIS) as described before. 33 Myeloma cells (Ͼ97% purity) were obtained.
Cell culture of freshly isolated myeloma cells and induction of apoptosis with paclitaxel and TRAIL
Freshly isolated, flow-sorted myeloma cells (2 × 10 5 /ml) were cultured in 0.5 ml of RPMI 1640 medium supplemented with 20% FCS (GIBCO, Grand Island, NY, USA), in a 24-well plate. Paclitaxel (0.5 m), or TRAIL (160 ng/ml) were added and wells were harvested after 24 and 48 h, and apoptosis determined by the Hoechst method. Spontaneous apoptosis in the freshly isolated myeloma cells was between 5-13% and 16-21% on day 1 and day 2 of culture, respectively. dim stem cells was performed by gating on the lymphoblastoid cell population (R1), followed by gating on the CD34
Flow
+ /CD45 dim cell population (R2). Flow-sorting was performed with the FACStar Plus Turbo-Fast Sorter (BDIS), as described before. 33 Freshly sorted CD34 + /CD45 dim stem cells (Ͼ93% purity) were cultured in triplicate cultures (1 × 10 5 cells/0.5 ml) in Iscove's medium (GIBCO) containing 10% autologous plasma, IL-3 (100 U/ml) and GM-CSF (100 U/ml) in a 24-well plate. TRAIL (160 ng/ml) was added and cultures were scored after 24 h and 48 h for cell number, viability and for quantitation of apoptosis, as described above for myeloma cells. For determination of CFU-GM and BFU-E colonies, freshly isolated purified CD34
dim cells (1000/ml) were suspended in a ready-made methylcellulose medium containing PHA conditioned medium (Stem Cell Technologies, Vancouver, BC, Canada) and 1 ml of the culture mixture was dispensed into 35-mm Petri dishes. Triplicate cultures with and without 160 ng/ml of TRAIL were initiated and CFU-GM and BFU-E colonies were scored on day 14 of culture.
Determination of bcl-2 protein expression by Western immunoblotting
Aliquots of freshly isolated, flow-sorted myeloma cells (ෂ3 × 10 5 cells) were washed (× 2) with PBS and total cellular protein was extracted as described before. 26 Equal amounts of protein (20 g) were loaded on to each lane and protein bands were resolved on SDS-PAGE. Gel electrophoresis, transfer of proteins to Immobilon-P nylon membrane, detection of specific bands by the avidin-biotin amplification method were all done as described by us before. 26 Visualization of specific bands by chemiluminescence and quantitation of protein bands by densitometry were all performed as previously described. 26 Antibodies to bcl-2 were from Dako (Carpinteria, CA, USA). A low molecular weight ladder (14.4-97 kDa) of biotinylated protein markers (BioRad, Hercules, CA, USA) was run for each gel. The bcl-2 (p26) band was identified according to its migration on the blot.
Results
Induction of apoptosis in myeloma cells by TRAIL
In order to extend our observations with Fas 30 to other member of the TNF family of proteins, we tested the effect of TRAIL -a newly identified member of this family of proteins which uses a similar pathway for transmitting an apoptotic signal. The effect of TRAIL on growth and apoptosis of ARP-1 and 8226 myeloma cell lines was tested between 0-160 ng/ml in a 2 day assay and the results are shown in Figures 1-4 . TRAIL reduced the number of viable cells in a time- 
Sensitivity of freshly isolated myeloma cells to paclitaxel and TRAIL-induced apoptosis
We have previously shown that bcl-2 might have an important role in survival of myeloma cells and in protection against apoptosis induced by different drugs. We have also shown that overexpression of bcl-2 in myeloma cell lines confers resistance to dexamethasone and paclitaxel-induced apoptosis. [25] [26] [27] [28] [29] Furthermore, recently we have shown that the frequency of myeloma cells in the bone marrow of 32 MM patients correlates with the levels of expression of bcl-2 (P = 0.008), measured by Western immunoblotting of purified myeloma cells. 40 These results suggest an important role for bcl-2 in survival of the myeloma clone in vivo. Therefore, it was of interest to test the effect of TRAIL on freshly isolated myeloma cells expressing variable levels of bcl-2. Hence, we purified CD38 bright CD45 negative myeloma cells from the bone marrow of six myeloma patients with either low or high levels of bcl-2 (see below). Mature myeloma cells with purity of Ͼ95% were obtained. An example is shown in Figure 5 positive myeloma cells). 33 Sorting of the mature myeloma cells resulted in a cell fraction with a purity of 97.6% ( Figure 5) .
Purified myeloma cells obtained from these selected MM patients were subsequently reanalyzed for bcl-2 expression by Western immunoblotting. The results are depicted in Figure  6 . A five-to 10-fold difference in the levels of expression of bcl-2 was observed between the low-bcl-2 expressing patients (MM 4-6) and the high-bcl-2 expressing patients (MM 1-3). For comparison, bcl-2 expression in 2 low-bcl-2 myeloma cell lines (ARP-1 and 8226; lanes 1 and 2, respectively) and their bcl-2 transfected counterparts (lanes 3 and 4) are also depicted in Figure 6 . We then tested the extent of TRAIL and paclitaxel-induced apoptosis of myeloma cells isolated from these MM patients (Table 1, Figure 6 ). A dose of 160 ng/ml of TRAIL or 0.5 m of paclitaxel was used to measure percent apoptotic cells in a 48-h cell culture assay. The results are summarized in Table 1 . Paclitaxel-induced apoptosis was low 
Figure 6
Western blot analysis of bcl-2 expression in freshly isolated myeloma cells. Protein extracts (20 g) from freshly isolated, flow-sorted myeloma cells were loaded on to each lane and proteins were resolved on SDS-PAGE. Extraction of proteins, SDS-PAGE electrophoresis, transfer of proteins to nylon membrane, immunoblotting, detection of specific protein bands and quntitation of results were done as described in the Methodology section. Twenty-three patients were analyzed and three patients with bcl-2 and 3 with low bcl-2 were picked and were rerun in groups of low or high bcl-2 expressing cells. following 24 and 48 h of treatment in the high bcl-2 expressing myeloma cells (1-8%, above background) and high in the low bcl-2-expressing myeloma cells (67-75% above background). In contrast to paclitaxel, all freshly isolated myeloma cells were equally sensitive to TRAIL with apoptosis ranging between 61-83% above background, regardless of the level of bcl-2 expression (Table 1) . Similar effects of TRAIL and paclitaxel were observed with ARH-77 cells (high-bcl-2) and 8226 and ARP-1 (low-bcl-2) MM cells lines.
TRAIL is not cytotoxic to freshly isolated CD34
+ /CD45 dim hematopoietic stem cells TRAIL receptors DR4 and DR5 are ubiquitously expressed in all normal tissues. [4] [5] [6] [7] [8] It was of interest to us to establish the in vitro toxicity of TRAIL to bone marrow stem cells. We, therefore, tested the sensitivity of freshly isolated peripheral blood CD34 + /CD45 dim stem cells from four MM patients undergoing peripheral blood stem cell collection for autologous transplantation, and from one normal bone marrow donor. A purity of Ͼ93% CD34 + /CD45 dim stem cells was obtained following flow sorting. An example is shown in Figure 7 in which a sorting purity of CD34
dim stem cells of 94% was obtained. Flow-sorted CD34
dim stem cells were cultured with or without 160 ng/ml of TRAIL for 24 or 48 h followed by cultures for 14 days in methylcellulose for CFU-GM and BFU-E colonies. The results are summarized in Table 2 . It is clear that TRAIL does not induce any significant apoptosis in peripheral blood or BM-derived flow-sorted CD34
dim stem cells, in a dose of TRAIL that induces substantial apoptosis in freshly isolated myeloma cells (Table  2, compare to Table 1 ). Furthermore, treatment with TRAIL did not result in a decrease in the number of CFU-GM or BFU-E colonies of purified CD34 + /CD45 dim stem cells (Table 2) .
Discussion
TRAIL was recently described as a death signal protein belonging to the large family of TNF signal transduction proteins. 4 TRAIL induces apoptosis in a similar way described for Fas and TNF␣, however, the exact adaptor molecules and caspases involved has not yet been identified. 4 TRAIL is expressed ubiquitously in normal and neoplastic cells of different tissues. However, it was reported that normal cells are resistant to TRAIL-induced apoptosis since they co-express a 'decoy' receptor (DcR-1/TRID in addition to the ordinary TRAIL receptors (DR4 and DR5). Decoy receptors lack the death domain portion of the molecule, and therefore act as an antagonist to the DR4 and DR5 receptors. 4, [34] [35] [36] [37] In a previous publication we demonstrated that Fas-induced apoptosis is not blocked by overexpression of bcl-2. 30 More recently, we demonstrated that TNF␣-induced apoptosis in myeloma cells is also resistant to bcl-2. 40 Here we demonstrate that purified human recombinant TRAIL containing the leucine-zipper domain is a potent inducer of apoptosis in human myeloma cell lines, as well as in freshly isolated myeloma cells with a dose-and time-dependent fashion. TRAILinduced apoptosis was reported before for the Ag8 mouse myeloma cell line using human recombinant TRAIL from a supernatant of TRAIL-producing, virus-infected cells, 38 however, the role of bcl-2 was not investigated. Most importantly, we observed similar dose response for TRAIL in myeloma cell lines expressing high levels of endogenous bcl-2, or in MM Fresh myeloma cells were purified by flow sorting of CD38 bright /CD45 negative as described in the Methodology section. Cells were cultured with paclitaxel (0.5 M) or TRAIL (160 ng/ml) and percent apoptotic cells was determined on day 1 and day 2 of culture as described in the Methodology section. -4) , or from bone marrow of a normal donor (N BM) were purified by flow sorting as described in the Methodology section. Cells were cultured with TRAIL (160 ng/ml) and percent apoptotic cells was determined on day 1 and day 2 of culture as described in the Methodology section. Apoptosis was tested twice and results were within ± 5% difference. Results from one experiment are shown. CFU-GM and BFU-E colony assays were performed in triplicate plates in a standard 14-day culture in methylcellulose following 24 cell lines transfected with bcl-2 expression vector. Furthermore, freshly isolated myeloma cells expressing low levels of endogenous bcl-2 were sensitive to both, paclitaxel and TRAIL. In contrast, freshly isolated myeloma cells with high levels of bcl-2 were resistant to paclitaxel, as was shown before for bcl-2-transfected myeloma cell lines, 25 but maintained sensitivity to TRAIL.
If TRAIL is to have a clinical benefit in the treatment of patients with MM, it should have no or a low level of bone marrow toxicity. Therefore, we studied the effect of TRAIL on freshly isolated peripheral blood and bone marrow-derived CD34 + hematopoietic stem cells. Our results clearly demonstrate that TRAIL is not cytotoxic to purified CD34 + hematopoietic stem cells in vitro. Furthermore, it has no adverse effect on the formation of CFU-GM and BFU-E colonies, at a concentration range that kill Ͼ80% of myeloma cells. Therefore, we can conclude that TRAIL might be a clinically useful drug for the treatment of patients with multiple myeloma. This is true especially for MM patients in relapse whose myeloma cells express relatively high levels of bcl-2 (Table 1, Figure 7) , and therefore are more resistant to conventional chemotherapy.
In conclusion, (1) TRAIL is a potent inducer of apoptosis in MM cell lines and in freshly isolated myeloma cells. (2) Similar to Fas and TNF␣, apoptosis induced by TRAIL is not blocked by bcl-2. (3) TRAIL is not cytotoxic to normal hematopoietic cells, and therefore it could be used for treatment of MM, alone, or in combination with other drugs.
Figure 7
Sorting of CD34 + /CD45 dim peripheral blood hematopoietic stem cells. Peripheral blood mononuclear cell apheresis collected from a MM patient mobilized with 6 g/m 2 of cytoxan plus 250 g/m 2 of GM-CSF 39 were stained for stem cell markers (CD34-PE and CD45-FITC) and sorted for CD34 + /CD45 dim stem cells as described in the Methodology section. This particular patient had a total of 8.6% stem cells. For sorting, a gate was established for forward scatter (FS) and side scatter (SS) with an R1 gate on the lymphoblastoid region (a). The next sorting gate was put on the CD34 + /CD45 dim cell population of stem cells (R2) (b). Sorted CD34 + stem cells were reanalyzed (c) and the results indicate a purity of 94% for this particular sort.
